Jazz Pharmaceuticals plc (JAZZ)

業務介紹

翻譯結果:

Jazz Pharmaceuticals plc是一家生物製藥公司,在美國、歐洲和國際上識別、開發和商業化各種未滿足的醫療需求的藥品。該公司擁有一個專注於神經科學(包括睡眠醫學和運動障礙)和腫瘤學(包括血液和實體腫瘤)領域的產品和產品候選物組合。其主要上市產品包括Xyrem、Sunosi、Erwinaze、Defitelio、Vyxeos liposome和Zepzelca。該公司還提供Xywav、JZP-324、JZP385、JZP458和JZP150等產品候選物。該公司與ImmunoGen、Codiak BioSciences、Pfenex、XL-protein GmbH和Redx Pharma plc有授權和合作協議。Jazz Pharmaceuticals plc於2003年成立,總部位於愛爾蘭都柏林。



Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

公司網址

https://www.jazzpharma.com